Combination of | |
---|---|
Calcium oxybate | Central nervous system depressant |
Magnesium oxybate | Central nervous system depressant |
Potassium oxybate | Central nervous system depressant |
Sodium oxybate | Central nervous system depressant |
Clinical data | |
Trade names | Xywav |
Other names | JZP-258 |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a621001 |
License data | |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Xywav is a medication used to treat cataplexy or excessive daytime sleepiness.[2][3] It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate.[2] It is a central nervous system (CNS) depressant and it is taken by mouth.[2]
Manufactured by the Jazz Pharmaceuticals company, it was approved for medical use in the United States in July 2020.[2][4][5]
Xywav is indicated for the treatment of cataplexy or excessive daytime sleepiness in people aged seven years of age and older with narcolepsy;[2][6] and for idiopathic hypersomnia.[6][7]
The US Food and Drug Administration (FDA) label for Xywav contains a boxed warning for central nervous system depression, abuse, and misuse.[2]
Slowed breathing, trouble breathing, sleep apnea.[2]
Confusion, hallucination, unusual or disturbing thoughts (abnormal thinking), anxiety, depression, suicidal thoughts or actions, increased tiredness, feelings of guilt or worthlessness, and difficulty concentrating.[2]
The sodium oxybate component of Xywav was granted orphan drug designation in November 1994 by the FDA.[8][6] Xywav is a prescription drug and a Schedule III controlled substance in the United States.[2]
In the testing phase of the drug, it was known as JZP-258.[9]
Calcium, magnesium, potassium, and sodium oxybate is another name for gamma hydroxybutyrate (GHB).[10][11]